Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics

Li, Jianmin; Li, Bing; Zhang, Jun; Hou, Lihua; Yu, Changming; Fu, Ling; Song, Xiaohong; Takata, Yasuyuki; Zhang, Jinglong; Ren, Jun; Xu, Chun’e; Chen, Wei

doi:10.1016/j.antiviral.2011.01.004

Cited by 4 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies showed that compared with rHuIFN-ω expressed in yeast with a specific activity of 7 × 10 7 IU/mg, rHuIFN-ω-Fc had a lower activity of 1.6 × 10 7 IU/mg when it was expressed in Chinese hamster ovary cells. Furthermore, the terminal half-life of rHuIFN-ω-Fc was 35-fold higher than that of rHuIFN-ω, and it exhibited better pharmacokinetics characteristics [40]. Perhaps rHuIFN-ω-Fc will become a new alternative antiviral drug for the treatment of chronic viral infections.…”

Section: Strategies To Improve the Antiviral Efficiency Of Ifn-ωmentioning

confidence: 99%

Interferon-omega: Current status in clinical applications

Zhao

Shao

et al. 2017

International Immunopharmacology

View full text Add to dashboard Cite

Since 1985, interferon (IFN)-ω, a type I IFN, has been identified in many animals, but not canines and mice. It has been demonstrated to have antiviral, anti-proliferation, and antitumor activities that are similar to those of IFN-α. To date, IFN-ω has been explored as a treatment option for some diseases or viral infections in humans and other animals. Studies have revealed that human IFN-ω displays antitumor activities in some models of human cancer cells and that it can be used to diagnose some diseases. While recombinant feline IFN-ω has been licensed in several countries for treating canine parvovirus, feline leukemia virus, and feline immunodeficiency virus infections, it also exhibits a certain efficacy when used to treat other viral infections or diseases. This review examines the known biological activity of IFN-ω and its clinical applications. We expect that the information provided in this review will stimulate further studies of IFN-ω as a therapeutic agent.

show abstract

Section: Strategies To Improve the Antiviral Efficiency Of Ifn-ωmentioning

confidence: 99%

Interferon-omega: Current status in clinical applications

Zhao

Shao

et al. 2017

International Immunopharmacology

View full text Add to dashboard Cite

show abstract

“…These TFs are sterol regulatory element binding transcription factor, activating enhancer binding protein 2-like YY1 site, interferon conserved sequence-binding protein, erythroid Kruppel-like factor gene, homeotic gene forkhead of Drosophila 8/hepatocyte nuclear factor 3/mouse forkhead lung protein, HNF-1A, interferon consensus sequence binding protein, and lymphocyte-enriched DNA binding protein LyF [129]. When expressed in yeast, recombinant human IFN-ω-Fc fusion protein (rhIFN-ω-Fc) has more specific activity than when expressed in a Chinese hamster ovary cell line; its terminal half-life is 35 times higher than rhIFN-ω [130]. However, an obvious drawback of IFN-ω is that it requires daily subcutaneous administration, which might influence patients’ compliance and impair its effectiveness.…”

Section: Hepatitismentioning

confidence: 99%

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Gong

Zhao

et al. 2018

Cell Physiol Biochem

137

111

View full text Add to dashboard Cite

The interferons (IFNs) are a primary defense against pathogens because of the strong antiviral activities they induce. IFNs can be classified into three groups: type I, type II and type III, according to their genetic, structural, and functional characteristics and their receptors on the cell surface. The type I IFNs are the largest group and include IFN-α, IFN-β, IFN-ε, IFN-ω, IFN-κ, IFN-δ, IFN-τ and IFN-ζ. The use of IFNs for the treatment of viral infectious diseases on their antiviral activity may become an important therapeutic option, for example, IFN-α is well known for the successful treatment of hepatitis B and C virus infections, and interest is increasing in the antiviral efficacy of other novel IFN classes and their potential applications. Therefore, in this review, we summarize the recent progress in the study of the biological activities of all the type I IFN classes and their potential applications in the treatment of infections with immunodeficiency virus, hepatitis viruses, and influenza viruses.

show abstract

“…Peg-IFN-λ1 is currently undergoing clinical development for the treatment of viral hepatitis (Duong et al, 2014). Recombinant human IFN-ω-Fc fusion protein represents a useful and promising and alternative antiviral agent especially for the treatment of chronic viral disease, such as hepatitis C virus infection (Li et al, 2011). Accordingly to our results, the IFN-ω should be suitable as antiviral agent against some avian strains and IFN-λ1s should be used against human infl uenza viruses.…”

Section: Discussionmentioning

confidence: 67%

Protective efficacy of IFN-ω AND IFN-λs against influenza viruses in induced A549 cells

Škorvanová¹,

Švančarová²,

Svetlíková³

et al. 2015

View full text Add to dashboard Cite

Th e interferon system represents one of the components of the fi rst line defence against infl uenza virus infection. Interferon omega (IFN-ω) is antigenetically diff erent from IFN-α and IFN-β and can aff ect patients who are resistant to these IFNs. To improve the biological characterization of IFN-ω, we compared its activity with those of type I and type III IFNs in induced A549 cells. Th e antiviral eff ect on IFN-stimulated A549 cells was most apparent aft er infection with avian infl uenza virus. IFN-ω had statistically signifi cant antiviral activity although less than IFN-β1a, IFN-λ1, or IFN-λ2. On the other hand, IFN-ω appeared more effi cient than IFN-α2. Our results also indicate that IFN-λs were more suitable against human highly pathogenic virus. In this case, IFN-λ1 and IFN-λ2 were more potent than type I IFNs.

show abstract

Preparation of CHO cell-derived rhIFN-ω-Fc with improved pharmacokinetics

Cited by 4 publications

References 26 publications

Interferon-omega: Current status in clinical applications

Interferon-omega: Current status in clinical applications

Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection

Protective efficacy of IFN-ω AND IFN-λs against influenza viruses in induced A549 cells

Contact Info

Product

Resources

About